Core Viewpoint - The article discusses a securities class action lawsuit against Telix Pharmaceuticals Ltd. due to alleged misrepresentations regarding the development of its therapeutic candidates and supply chain issues, with a significant stock decline following regulatory setbacks [2][3]. Regulatory Failures - The lawsuit highlights two major regulatory events that allegedly corrected market perceptions of Telix's business: - On July 22, 2025, Telix disclosed an SEC subpoena related to its prostate cancer therapeutic candidates, which raised concerns about misleading disclosures on drug development progress [4]. - On August 28, 2025, the FDA rejected the Zircaix application, citing deficiencies in Chemistry, Manufacturing, and Controls (CMC) and documented Form 483 deficiencies at third-party manufacturers [4]. Stock Impact - Following these regulatory revelations, Telix's American Depositary Shares (ADSs) experienced a sharp decline, with a total stock drop of 21% after the final regulatory news [2][4]. Legal Issues - The complaint raises key legal issues, including whether Telix made misleading disclosures regarding drug development progress and whether the company concealed foundational weaknesses in its third-party supply chain and manufacturing processes [4]. Investor Actions - Hagens Berman, the law firm leading the litigation, is actively advising investors who purchased TLX ADSs during the class period and suffered losses due to undisclosed supply chain and therapeutic progress flaws [5]. Important Dates - The deadline for investors to move the court for appointment as lead plaintiff in the lawsuit is January 9, 2026 [1][6].